Core Viewpoint - The company believes that trade policy adjustments and export restrictions on yttrium will not significantly impact its cost advantages or operational performance [1] Group 1 - The company reassured investors that increased tariffs and long-term export bans on yttrium will not alter its cost advantages [1] - The company will continue to monitor policy changes and ensure supply chain security [1]

证券代码： 301580 证券简称：爱迪特 公告编号：2025-044 爱迪特（秦皇岛）科技股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会不存在否决议案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 3、本次股东会对中小投资者进行单独计票。 一、会议召开和出席情况 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）2025 年第三次 临时股东会（以下简称"股东会"）现场会议于 2025 年 9 月 16 日下午 14:30 在 河北省秦皇岛市经济技术开发区都山路 9 号公司二楼会议室召开；同时使用深 圳证券交易所交易系统网络投票于 2025 年 9 月 16 日交易时间接受网络投票， 即 9:15-9:25，9:30-11:30 和 13:00-15:00；使用深圳证券交易所互联网投票系统 于 2025 年 9 月 16 日 9:15-15:00 期间接受网络投票。 股东出席的总体情况：出席本次股东会的股东及股东的委托代理人共计 77 人，代表公司有表决权的股份 36 ...

北京市中伦律师事务所 关于爱迪特（秦皇岛）科技股份有限公司 2025 年第三次临时股东会的 法律意见书 致：爱迪特（秦皇岛）科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受爱迪特（秦皇岛）科技股 份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2025 年第三次 临时股东会（以下简称"本次股东会"）的合法性进行见证并出具法律意见。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）和《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等现行有效的法律、法规、规范性文件 以及《爱迪特（秦皇岛）科技股份有限公司章程》（以下简称"《公司章程》"）、 《爱迪特（秦皇岛）科技股份有限公司股东会议事规则》（以下简称"《股东会 议事规则》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司本次股东会的有关文件和材料。 本所律师得到公司如下保证，即其已提供了本所律师认为出具本法律意见书所必 需的材料，所提供的原始材料、副本、复印件、 ...

Group 1 - Aidi Te (Hangzhou) Digital Technology Co., Ltd. has been established with a registered capital of 20 million yuan [1] - The company's business scope includes artificial intelligence basic software development, artificial intelligence application software development, Internet of Things technology services, and data processing and storage support services [1] - Aidi Te fully owns the newly established digital technology company [1]

Group 1 - The company, Aidi Te (301580), received FDA Class II medical device registration certificate number k251415 on August 15, 2025 [1] - The company adheres to information disclosure requirements by reporting the status of medical device registration certificates in its semi-annual and annual reports [1]

Group 1 - The core viewpoint is that Aidi Te (301580) has not yet initiated any specific cooperation projects with Alibaba as of September 15 [1] - The company expresses an open attitude towards potential future collaborations and commits to timely information disclosure in accordance with relevant regulations if any plans arise [1]

中信建投证券股份有限公司关于 爱迪特（秦皇岛）科技股份有限公司 2025 年上半年度跟踪报告 | 保荐人名称：中信建投证券股份有限公司 | 上市公司简称：爱迪特 | | --- | --- | | 保荐代表人姓名：张铁 | 联系电话：021-68801592 | | 保荐代表人姓名：周俊峰 | 联系电话：010-86451688 | 一、保荐工作概述 | 项 目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2.督导公司建立健全并有效执行规章制度的情 | | | 况 | | | （1）是否督导公司建立健全规章制度（包括但 | | | 不限于防止关联方占用公司资源的制度、募集 | 是 | | 资金管理制度、内控制度、内部审计制度、关 | | | 联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 次 1 | | （2）公司募集资金项目进展是否与信息披露文 | ...

Group 1 - The first national 3D printing drug production license has been issued in Nanjing, marking a significant step in the development and industrialization of 3D printing technology in pharmaceuticals [2] - The licensed entity, Nanjing SanDieJi Pharmaceutical Technology Co., has a production capacity of 300 million 3D printed drug pieces annually, making it the largest commercial production base for 3D printed drugs globally [2] - 3D printing technology offers advantages over traditional pharmaceutical manufacturing, including complex drug structure design, digital drug development, precise drug delivery, and intelligent manufacturing [2] Group 2 - The 3D printing market in China is projected to reach approximately 423 billion yuan in 2024 and is expected to exceed 450 billion yuan by 2025, driven by the increasing application of 3D printing products and the release of pent-up demand for 3D printing equipment [3] - The application fields of 3D printing are expanding, covering industries such as aerospace, automotive, biomedical, construction, and consumer goods, with rapid growth in the consumer electronics sector [3] Group 3 - Seven 3D printing concept stocks have been frequently researched by institutions, with notable companies including Dazong Laser, Aobi Zhongguang-UW, and Yuedan New Materials, among others [5] - The average increase in the stock prices of 3D printing concept stocks this year is 37.05%, with Zhongzhou Special Materials leading with a 192% increase [5][6] - Companies like Aidi Te and Huazhu High-Tech are actively involved in the 3D printing sector, with Aidi Te having launched multiple 3D printers and Huazhu High-Tech developing its own 3D printing equipment and materials [4][5] Group 4 - Xie Chuang Data (300857) has seen its stock price rise significantly, reaching a market value of 44.303 billion yuan, with a maximum increase of over 11 times compared to its three-year low [7] - The company reported a revenue of 4.944 billion yuan in the first half of the year, a year-on-year increase of 38.18%, with a net profit of 432 million yuan, reflecting a growth of 20.76% [7]

Core Insights - Jiangsu Province has issued the first national drug production license utilizing 3D printing technology, marking a significant advancement in the research and industrialization of 3D printed pharmaceuticals in China [1] - The confidence of pharmaceutical companies in 3D printing technology is greatly encouraged by this development [1] Group 1: Market Performance - As of September 10, 2023, 3D printing concept stocks have seen an average increase of 37.05% this year [1] - Zhongzhou Special Materials has the highest increase at 192%, followed by Huazhu High-Tech with an increase of 111.02% [1] Group 2: Institutional Research - Seven 3D printing concept stocks have been investigated by institutions 10 times or more this year, including Dazhu Laser, Aobi Zhongguang-UW, and others [1] - Dazhu Laser leads with 72 institutional investigations, while Aobi Zhongguang-UW has been investigated 21 times [2]

Core Viewpoint - As of September 4, 2023, the company has not received any intentions or plans from Alibaba Network (China) Technology Co., Ltd. regarding increased investment [1] Company Summary - The company, Aidi Te (301580), responded to investor inquiries on an interactive platform [1] - There is currently no indication of potential investment from Alibaba [1]